Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record.

Hematologic Complications of Immune Checkpoint Inhibitors

Open access
Davis, Elizabeth J., Salem, Joe-Elie, Young, Arissa, Green, Jennifer R., Ferrell, P. Brent, Ancell, Kristin K., Lebrun-Vignes, Benedicte, Moslehi, Javid J., Johnson, Douglas B.·2019·The Oncologist

Abstract

Immune checkpoint inhibitors have improved outcomes for patients with numerous hematological and solid cancers. Hematologic toxicities have been described, but the spectrum, timing, and clinical presentation of these complications are not well understood. We used the World Health Organization's pharmacovigilance database of individual-case-safety-reports (ICSRs) of adverse drug reactions, VigiBase, to identify cases of hematologic toxicities complicating immune checkpoint inhibitor therapy. We identified 168 ICSRs of immune thrombocytopenic purpura (ITP), hemolytic anemia (HA), hemophagocytic lymphohistiocytosis, aplastic anemia, and pure red cell aplasia in 164 ICSRs. ITP (n = 68) and HA (n = 57) were the most common of these toxicities and occurred concomitantly in four patients. These events occurred early on treatment (median 40 days) and were associated with fatal outcome in 12% of cases. Ipilimumab-based therapy (monotherapy or combination with anti-programmed death-1 [PD-1]) was associated with earlier onset (median 23 vs. 47.5 days, p = .006) than anti-PD-1/programmed death ligand-1 monotherapy. Reporting of hematologic toxicities has increased over the past 2 years (98 cases between January 2017 and March 2018 vs. 70 cases before 2017), possibly because of increased use of checkpoint inhibitors and improved recognition of toxicities. Future studies should evaluate incidence of hematologic toxicities, elucidate risk factors, and determine the most effective treatment algorithms. Key Points: Immune-mediated hematologic toxicities are a potential side effect of immune checkpoint inhibitors (ICIs). Providers should monitor complete blood counts during treatment with ICIs. Corticosteroids are the mainstay of treatment for immune-mediated hematologic toxicities. Further research is needed to define patient-specific risk factors and optimal management strategies for hematologic toxicities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2018-0574

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 177

Metadata

Authors
Davis, E. J., Salem, J.-E., Young, A., Green, J. R., Ferrell, P. B., Ancell, K. K., Lebrun-Vignes, B., Moslehi, J. J., & Johnson, D. B.
Venue
The Oncologist
Published
2019-02-28
Volume
24
Issue
5
Pages
584-588
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2917423789
Cited by
177
References
0
FWCI
8.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hematologic Complications of Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1634/theoncologist.2018-0574
The paper
Davis, E. J., Salem, J.-E., Young, A., Green, J. R., Ferrell, P. B., Ancell, K. K., Lebrun-Vignes, B., Moslehi, J. J., & Johnson, D. B. (2019). Hematologic Complications of Immune Checkpoint Inhibitors. The Oncologist. https://doi.org/10.1634/theoncologist.2018-0574

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.